心脏收缩力调节器及其临床应用进展  

Research Update on Cardiac Contractility Modulation and Its Clinical Application

作　　者：刘存存 华伟 LIU Cuncun;HUA Wei(Arrhythmia Center,National Center for Cardiovascular Diseases and Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]中国医学科学院、北京协和医学院、国家心血管病中心、阜外医院心律失常中心,北京100037

出　　处：《中国循环杂志》2023年第4期469-473,共5页Chinese Circulation Journal

摘　　要：目前心力衰竭(心衰)已成为全球流行性疾病,尽管治疗方案不断优化,但预后仍较差。对于射血分数降低的心衰(HFrEF)患者,仅少部分符合心脏再同步化治疗指征,但对于QRS时限<130 ms的HFrEF患者而言,器械治疗仍存在一定缺陷。心脏收缩力调节器(CCM)是一种可以通过调节钙离子浓度及异常基因表达来增加心肌收缩力而不产生额外耗氧量的新型器械,已被证实具有很好的安全性及有效性。本文总结CCM的作用机制以及近几年在心衰患者中的临床应用进展。Heart failure(HF)has become a global epidemic disease.The prognosis is still poor despite the continuous optimization of treatment options.Only a small number of patients with heart failure with reduced ejection fraction(HFrEF)are suitable candidates for cardiac resynchronization therapy,and instrumental therapy for HFrEF patients with QRS<130 ms remains challenging.Cardiac contractility modulation(CCM)is a new device that can increase myocardial contractile force by regulating calcium ion concentration and abnormal gene expression without inducing additional oxygen consumption.Clinical safety and efficacy have been documented in various clinical studies.The purpose of this review is to summarize the research advances on mechanism of CCM and its clinical application in HF patients.

关 键 词：心脏收缩力调节器 心力衰竭 心脏同步化治疗 心室重构 

分 类 号：R54[医药卫生—心血管疾病]